GlassScriptPhysician profile
William Eugene Marcrum
NPI 1629051792
$10,763.89
in general payments reported to CMS, 2019-2025
47 companies · $666 in 2025
The $666 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $1,432 · 2021: $2,348 · 2022: $1,844 · 2023: $1,817 · 2024: $1,256 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,739.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,518.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,046.43 | 2019-2025 | |
| Amgen INC. | $787.81 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $778.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $575.90 | 2019-2025 | |
| Amarin Pharma, INC. | $547.78 | 2019-2021 | |
| Novo Nordisk INC | $547.39 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $468.57 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $458.53 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $434.36 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $403.11 | 2019-2025 | |
| Lilly USA, LLC | $301.82 | 2019-2023 | Emgality, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.78 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.65 | 2019-2024 | Trulance, Xifaxan |
| Allergan, INC. | $193.11 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Marcrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.